(Financial Information to Follow)
NORTHWEST BIOTHERAPEUTICS, INC.(A Development Stage Company)CONSOLIDATED BALANCE SHEET(in thousands, except per share data)December 31,20122011ASSETSCurrent assets:Cash and cash equivalents$
24Prepaid expenses and other current assets11294Total current assets7,458118Property and equipment:Laboratory equipment6029Office furniture and other equipment172172Less accumulated depreciation and amortization(137)(123)Property and equipment, net9578Deposit and other non-current assets1716Total assets$
212LIABILITIES, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' DEFICITCurrent liabilities:Accounts payable (includes related party of $3,397 and $1,589 in 2012 and 2011, respectively)$
3,808Accrued expenses (includes related party of $28 and $630 in 2012 and 2011, respectively)5892,815Note payable (includes related party of $0 and $2,056 in 2012 and 2011, respectively)9345,205Convertible notes, net (includes related party of $0 and $3,588 in 2012 and 2011, respectively)1,0568,420Embedded derivative liability-601Liability for reclassified equity contracts-29,903Total current liabilities10,74450,752Non-current liabilities:Notes payable-200Convertible notes payable, net1,8821,433Total long term liabilities1,8821,633Total liabilities12,62652,385Redeemable common stock ($0.001 par value)11,017-Stockholders' deficit:Preferred stock ($0.001 par value); 40,000,000 and 20,000,000 shares authorized; 0 and 0 shares issued and outstanding as of December 31, 2012 and December 31, 2011, respectively--Common stock ($0.001 par value); 450,000,000 and 150,000,000 shares authorized; 26,545,828 and 9,334,101 shares issued and outstanding as of December 31, 2012 and December 31, 2011, respectively27150Additional paid-in capital303,188199,605Deficit accumulated during the development stage(319,098)(251,778)Cumulat
|SOURCE Northwest Biotherapeutics|
Copyright©2012 PR Newswire.
All rights reserved